Barclays raised the firm’s price target on RadNet (RDNT) to $85 from $79 and keeps an Overweight rating on the shares. The firm walked away from the RSNA Conference with a greater appreciation for the competitive advantages and differentiation across DeepHealth’s suite of products, including speed, integration, and usability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDNT:
- RadNet’s DeepHealth launches new AI-powered solutions at RSNA 2024
- RadNet’s DeepHealth expands FDA clearance for SmartMammo solution
- RadNet price target raised to $94 from $80 at Truist
- RadNet’s DeepHealth expands FDA clearance for SmartMammo solutionGE
- RadNet Achieves Record Revenue and Adjusts 2024 Guidance